Fate Therapeutics第三季度每股收益（0.27美元）超过（0.29美元）预期，销售额174.1万美元超过153.5万美元预期

Fate Therapeutics (NASDAQ: FATE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 32.5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $1.741 million which beat the analyst consensus estimate of $1.535 million by 13.42 percent. This is a 43.36 percent decrease over sales of $3.074 million the same period last year.